Compare Boston Scientific Corporation (BSX) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Estee Lauder Companies Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Estee Lauder Companies Inc trades at $82.25 (market cap $29.25B). The key difference: Boston Scientific Corporation is far larger — about 2.3× Estee Lauder Companies Inc's market cap, and Estee Lauder Companies Inc pays a 1.73% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | EL | |
|---|---|---|
Market Cap | $66.37B | $29.25B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $119.61 |
52-Week Low | $42.63 | $67.23 |
Enterprise Value | $75.94B | $35.43B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Estée Lauder (EL) trades at $81.15, down 1.83% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows negative net income and declining revenue trends, though recent quarters have beaten EPS estimates. Analyst consensus is divided with a $90.60 price target, while technical indicators point to support near $80.
Outlook remains cautious due to profitability challenges and competitive pressures, but potential upside exists if cost controls and innovation drive margin recovery. Key risks include sustained earnings pressure and macroeconomic sensitivity in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
